Clinical laboratories and healthcare systems implementing in vitro diagnostics
Key Highlights
Rapid and accurate infectious diseases diagnostics are essential for antimicrobial stewardship and combating antimicrobial resistance.
Market access for IVDs is challenged by high upfront costs, inconsistent coverage and reimbursement policies, and evolving regulatory landscapes.
Clinicians, pharmacists, and laboratory professionals must engage in advocacy to influence regulation, reimbursement, and guideline inclusion to improve diagnostic accessibility.
Guideline-Based Recommendations
Diagnosis
Utilize rapid and accurate IVDs to guide targeted antimicrobial therapy and reduce unnecessary antibiotic use.
Management
Engage in coordinated evidence-based communication with regulatory bodies, payors, and professional societies to support IVD adoption.
Strengthen relationships with industry partners, regulatory bodies, government agencies, professional societies, and patient advocacy groups.
Monitoring & Follow-up
Monitor evolving regulatory and reimbursement policies affecting IVD availability and coverage.
Risks
High upfront costs and inconsistent reimbursement may limit access to essential diagnostics.
Lack of clinician and laboratory engagement in advocacy may impede innovation and widespread adoption.
Patient & Prescribing Data
Patients requiring infectious diseases diagnostics for antimicrobial stewardship
Access to effective IVDs supports targeted therapy, reduces unnecessary antibiotic use, and improves patient outcomes.
Clinical Best Practices
Clinicians and laboratory professionals should actively participate in advocacy efforts to influence health policy and reimbursement decisions.
Generate and present robust clinical and economic evidence to payors to support coverage and reimbursement.
Stay informed about regulatory pathways and reimbursement mechanisms to facilitate timely adoption of innovative diagnostics.
